Condition: Sickle Cell Disease · Thalassemia · Sponsor: Novo Nordisk A/S
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country.
This description comes directly from the study's public registry record.
Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com
Always discuss trial participation with your own doctor first.
| Univ of Alabama Birmingham | Birmingham, Alabama, United States | Active Not Recruiting |
| Phoenix Children's Hsptl | Phoenix, Arizona, United States | Recruiting |
| Children's Hospital Los Angeles - Endocrinology | Los Angeles, California, United States | Active Not Recruiting |
| Children's Hospital Los Angeles - Endocrinology | Los Angeles, California, United States | Recruiting |
| UCSF Oakland Benioff ChildHosp | Oakland, California, United States | Active Not Recruiting |
| UCSF Oakland Benioff ChildHosp | Oakland, California, United States | Recruiting |
| Children's Hosp Of Orange | Orange, California, United States | Completed |
| University Of California Irvine | Orange, California, United States | Recruiting |
| University of Connecticut | Farmington, Connecticut, United States | Active Not Recruiting |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | Completed |
| Foundation for Sickle Cell Disease Research | Hollywood, Florida, United States | Recruiting |
| Univ of Miami/SCCC | Miami, Florida, United States | Completed |
+ 93 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06609226